Telix new drug application for prostate cancer imaging product accepted by US FDA

Telix Pharmaceuticals

24 November 2020 - Telix Pharmaceuticals announces new drug application for TLX591-CDx.

Telix Pharmaceuticals announces new drug application for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), a radiopharmaceutical targeting prostate-specific membrane antigen for the imaging of prostate cancer using positron emission tomography, has been accepted for filing by the United States FDA.

Read Telix Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , US , Dossier , Diagnostic agent